Neogap acquires TCER Oncology AB, strengthening its position in personalised immunotherapy

Swedish biotechnology company Neogap Therapeutics, which is developing personalised immunotherapy, announces its acquisition of the remaining 30 per cent of the shares in its subsidiary, TCER Oncology AB. This acquisition will broaden Neogap's patent portfolio and strengthen the company's pipeline of potential drug candidates, further consolidating Neogap's position in the field.Previously, Neogap owned 70 per cent of the shares in TCER Oncology AB. During the second quarter of this year, the remaining 30 per cent was acquired from Rolf Kiessling and Stina Wickström in exchange for Neogap